ArticleExperimental and therapeutic medicine2017
MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.Scientific reports · 2021Article
- miR-138 Reduces the Dysfunction of T Follicular Helper Cells in Osteosarcoma via the PI3K/Akt/mTOR Pathway by Targeting PDK1.Computational and mathematical methods in medicine · 2021Article
- The Effect of miR-138 on the Function of Follicular Helper T Cells and the Differentiation of B Cells in Osteosarcoma.Computational and mathematical methods in medicine · 2021Article
- Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations.Nature communications · 2020Article
- miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
- MicroRNA-466 inhibits osteosarcoma cell proliferation and induces apoptosis by targeting CCND1.Experimental and therapeutic medicine · 2018Article
- TIPE Family of Proteins and Its Implications in Different Chronic Diseases.International journal of molecular sciences · 2018Review
Corrections and comments
- Retraction · 2021-10-04Author Unresponsive · Duplication of/in Image · Investigation by Third Party · Paper Mill · · see also: https://pubpeer.com/publications/A47A98B8C645225113CF541725E9B9
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRs) have a critical role in the development and malignant progression of osteosarcoma (OS), but the underlying mechanisms have largely remained elusive. The present study aimed to explore the regulatory role of miR-138 in OS growth and metastasis and investigated the associated mechanisms. Reverse-transcription quantitative polymerase chain reaction and western blot analysis were performed to examine the miR-138 and protein expression levels in OS and normal bone tissues and cell lines. An MTT assay and a Transwell assay were used to assess cell proliferation and invasion. Flow cytometry was used to analyze the cell cycle and determine the apoptotic rate. A luciferase reporter assay was used to confirm the targeting association between miR-138 and tumor necrosis factor-α-induced protein 8 (TNFAIP8). It was found that miR-138 was downregulated in OS tissues and cell lines. Overexpression of miR-138 decreased the proliferation, cell cycle progression and invasion of OS cells, while inducing cell apoptosis. TNFAIP8 was then identified as a novel target of miR-138. Similarly to the effects of miR-138 overexpression, inhibition of TNFAIP8 also inhibited OS cell proliferation, cell cycle progression and invasion, and induced cell apoptosis. In addition, miR-138 overexpression as well as downregulation of TNFAIP8 reduced OS cell invasion via inhibition of matrix metalloproteinase-2 and -9 expression. Taken together, the results of the present study demonstrated that miR-138 directly targets TNFAIP8 and acts as a tumor suppressor in OS, suggesting that the miR-138/TNFAIP8 interaction may become a promising therapeutic target for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.